GENE ONLINE|News &
Opinion
Blog

Boehringer Ingelheim
Boehringer, Kinoxis Ink $181 Million Pact To Target Oxytocin Receptors
2023-05-08
Boehringer to Leverage RetinAI’s AI Tech to Further Geographic Atrophy Research
2023-04-23
JPM23: Partnerships Take off From JP Morgan Healthcare Conference 2023 Day One
2023-01-10
Eli Lilly and BI Notch Clinical Win for Kidney Disease Drug
2022-11-07
Boehringer Ingelheim, Evotec and bioMérieux Form $40M Venture to Combat Antimicrobial Resistance
2022-07-07
Eli Lilly and Boehringer Ingelheim’s Jardiance Shows Encouraging Phase 3 HFpEF Data
2021-07-07
Boehringer Ingelheim’s Newest Acquisition Reinforces its Focus on Immuno-Oncology
2020-12-14
The Evolution of Lung Cancer Therapies at a Glance
2020-04-16
Boehringer Ingelheim’s Ofev Becomes First FDA Approved Treatment for Progressive Interstitial Lung Diseases
2020-03-11
Boehringer Ingelheim’s New Drug – Nintedanib – Lowers Pulmonary Fibrosis by 57%
2019-10-21
Weekly in Asia 2019|JULY
2019-07-11
LATEST
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
Rice University Engineers Develop Miniature Brain Stimulator for Safer and Less-invasive Neuromodulation
2024-04-17
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
Join Us for the SABPA OC/LA 16th Annual Biomedical Forum!
2024-04-16
Sequencing Revolution Spotlights the Titans of NGS Innovation
2024-04-16
EVENT
2024-04-20
16th SABPA OC/LA Annual Biomedical Forum
The Beckman Center, 100 Academy, Irvine, CA, 92617
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top